{"id":4682,"date":"2025-03-31T18:12:16","date_gmt":"2025-03-31T18:12:16","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/simvastatin-txt\/"},"modified":"2025-03-31T18:12:16","modified_gmt":"2025-03-31T18:12:16","slug":"simvastatin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/simvastatin-txt\/","title":{"rendered":"simvastatin.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nHMG CoA reductase inhibitor:Primary hypercholesterolaemia

DOSE IN NORMAL RENAL FUNCTION <\/H3>10\u201380 mg at night

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :418.6<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>95<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 13<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :54<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :1.9\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
  • 10 to 20 &nbsp &nbsp : mg daily. In severe renal impairment doses above 10 mg should be used with caution (doses up to 40 mg have been used)

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anti-arrhythmics: increased risk of myopathy with amiodarone \u2013 do not exceed 20 mg of simvastatin.1\n
  • Antibacterials: increased risk of myopathy with clarithromycin, daptomycin, telithromycin and erythromycin \u2013 avoid concomitant use; increased risk of myopathy with fusidic acid\n
  • Anticoagulants: effects of coumarins enhanced\n
  • Antifungals: increased risk of myopathy with itraconazole, posaconazole or ketoconazole and possibly miconazole \u2013 avoid concomitant use; possibly increased risk of myopathy with imidazoles and triazoles\n
  • Antivirals: increased risk of myopathy with atazanavir, indinavir, nelfinavir, ritonavir or saquinavir and possibly amprenavir or lopinavir \u2013 avoid concomitant use; concentration reduced by efavirenz\n
  • Calcium-channel blockers: increased risk of myopathy with verapamil and possibly diltiazem \u2013 do not exceed 20 mg of simvastatin with verapamil or 40 mg with diltiazem.1\n
  • Ciclosporin: increased risk of myopathy \u2013 do not exceed 10 mg of simvastatin.1Grapefruit: increased risk of myopathy \u2013 avoid concomitant useHormone antagonists: possibly increased risk of myopathy with danazol \u2013 do not exceed 10 mg of simvastatin.1Lipid-lowering agents: increased risk of myopathy with fibrates \u2013 do not exceed 10 mg of simvastatin except with fenofibrate;1 gemfibrozil \u2013avoid; and nicotinic acid

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE HMG CoA reductase inhibitor:Primary hypercholesterolaemia DOSE IN NORMAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4682","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4682"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4682\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}